PEG-IFNα-2a治疗HBeAg阳性慢性乙型肝炎48周应答不佳患者序贯替诺福韦酯24周疗效分析

吕莹; 陈晓蓉

doi:10.3969/j.issn.1001-5256.2016.11.010

PEG-IFNα-2a治疗HBeAg阳性慢性乙型肝炎48周应答不佳患者序贯替诺福韦酯24周疗效分析

DOI: 10.3969/j.issn.1001-5256.2016.11.010

吕莹,
陈晓蓉

复旦大学附属上海市公共卫生临床中心中医科

详细信息

中图分类号: R512.62
计量
- 文章访问数: 3573
- HTML全文浏览量: 20
- PDF下载量: 424
- 被引次数: 0
出版历程
- 出版日期: 2016-11-20

Clinical effect of 24-week TDF versus ADV sequential therapy in HBeAg-positive chronic hepatitis B patients with suboptimal response to 48-week pegylated interferon-α-2a treatment

摘要

摘要:
目的观察PEG-IFNα-2a单药治疗HBeAg阳性慢性乙型肝炎（CHB）患者48周血清学应答不佳序贯应用替诺福韦酯（TDF）治疗24周的疗效。方法纳入2015年6月-2016年2月就诊于上海市公共卫生临床中心,经PEG-IFNα-2a 180μg/周治疗48周HBeAg未发生血清学转换的CHB患者共21例。其中11例患者加用TDF 300 mg/d,12周后停用PEG-IFNα-2a,继续予TDF单药治疗12周;10例患者序贯阿德福韦酯（ADV）10 mg/d单药治疗24周。治疗12、24周时检测HBV DNA,肝、肾功能,HBV血清学标志物等指标,对比两组疗效。两组计量资料比较,满足正态分布的组间比较采用独立样本t检验,组内比较采用配对t检验;不满足正态分布的采用Mann-Whithey U检验。计数资料比较采用Fisher确切概率法。结果治疗12、24周时,两组患者的HBs Ag、HBeAg水平差异无统计学意义（P值均>0.05）。治疗24周时,TDF组患者HBeAg转换率（18.2%,2/11）与ADV组（10.0%,1/10）比较差异无统计学意义（P>0.05）;...
- 肝炎,乙型,慢性 /
- 肝炎e抗原,乙型 /
- 干扰素α-2a /
- 替诺福韦酯 /
- 治疗
Abstract:
Objective To investigate the clinical effect of 24- week tenofovir disoproxil fumarate( TDF) sequential therapy in HBeAg- positive chronic hepatitis B( CHB) patients with suboptimal serological response to 48- week pegylated interferon- α- 2a( Peg- IFN- α- 2a) monotherapy. Methods A total of 21 patients who did not achieve HBeAg seroconversion after the 48- week Peg- IFN- α- 2a monotherapy at a dose of 180 μg / week were enrolled. Among these patients,11 were given TDF 300 mg / d in addition,the withdrawal of Peg- IFN- α- 2a after 12 weeks,and TDF monotherapy for 12 weeks; 10 were given sequential adefovir dipivoxil( ADV) monotherapy at a dose of 10 mg / d for 24 weeks. The indicators including HBV DNA,liver and renal function,and HBV serological markers were measured at weeks 12 and 24 of treatment,and the clinical outcome was compared between the two groups. The independent samples t- test was used for comparison of normally distributed continuous data between groups and the paired t- test was used for comparison of normally distributed continuous data within one group; the Mann- Whitney U test was used for comparison of non- normally distributed continuous data between groups. The Fisher's exact test was used for comparison of categorical data. Results At weeks 12 and 24 of treatment,there were no significant differences in HBs Ag and HBeAg levels between groups( both P > 0. 05). At week 24 of treatment,there was no significant difference in HBeAg seroconversion rate between the TDF group and the ADV group [18. 2%( 2 /11) vs 10. 0%( 1 /10),P > 0. 05]. At weeks 12 and 24 of treatment,the TDF group had significant reductions in HBeAg compared with baseline( 1. 75 ± 0. 59 log10 S / CO、1. 61 ± 0. 70 log10 S / CO vs1. 86 ± 0. 58 log10 S / CO,P = 0. 017 and 0. 027). At week 24 of treatment,the TDF group had a significantly lower alanine aminotransferase( ALT) level than the ADV group[21. 0( 15.0-27.0) U/L vs 33. 0( 21. 5-63. 5) U/L,P =0.046]. There were no significant differences in estimated glomerular filtration rate at weeks 12 and 24 of treatment between the two groups( both P > 0. 05). Conclusion As for CHB patients with suboptimal serological response to 48- week Peg- IFN- α- 2a monotherapy,addition of TDF for 12 weeks and then TDF monotherapy for 12 weeks helps to achieve greater reductions in serum ALT and HBeA g levels compared with sequential ADV therapy.
- hepatitis B,chronic /
- hepatitis B e agtigens /
- interferon alfa-2a /
- tenofovir /
- therapy

HTML全文

参考文献(17)

[1]LONDON WT,EVANS AA,Mc GLYNN K,et al.Viral,host and environmental risk factors for hepatocellular carcinoma:a prospective study in Haimen City,China.[J].Intervirology,1995,38(3-4):155-161.

[2]Mc CLUNE AC,TONG MJ.Chronic hepatitis B and hepatocellular carcinoma[J].Clin Liver Dis,2010,14(3):461-476.

[3] LU FM,ZHUANG H.Management of hepatitis B in China[J].Chin Med J,2009,122(1):3-4.

[4]ILOEJE UH,YANG HI,SU J,et al.Predicting cirrhosis risk based on the level of circulating hepatitis B viral load[J].Gastroenterology,2006,130(3):678-686.

[5] Chinese Society of Hepatology,Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ.

[6]LIAW YF,JIA JD,CHAN HLY,et al.Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C[J].Hepatology,2011,54(5):1591-1599.

[7]LOK AS,Mc MAHON BJ.Chronic hepatitis B:update 2009[J].Hepatology,2009,50(3):661-662.

[8]LEI N,JIN Y,HE ZM,et al.The efficacy of combination therapy based on TDF in chronic hepatitis B patients with nucleos(t)ide analogues suboptimal response or resistance[J].Beijing Med J,2014,36(12):1012-1016.(in Chinese)雷娜,金怡,何智敏,等.基于替诺福韦酯的联合抗病毒治疗方案对应答不佳或耐药慢性乙型肝炎患者的疗效[J].北京医学,2014,36(12):1012-1016.

[9]WANG JB,KANG HY,CAO XG,et al.The effect of LAM or ADV add-on therapy for HBe Ag negative chronic hepatitis B patients with suboptimal response to PEG-IFN[J].Int J Virol,2015,22(5):310-314.(in Chinese)王建彬,康海燕,曹雪改,等.聚乙二醇干扰素应答不佳HBe Ag阴性慢性乙肝患者加用拉米夫定或阿德福韦酯疗效观察[J].国际病毒学杂志,2015,22(5):310-314.

[10]LI HY,YANG ZH,MA LL,et al.Clinical efficaly of telbivudine and interferon in treatment of HBe Ag-positive chronic hepatitis B:a comparative study[J].J Clin Hepatol,2015,31(4):526-529.(in Chinese)李火炎,杨兆辉,马丽丽,等.替比夫定与干扰素α治疗HBe Ag阳性慢性乙型肝炎患者临床疗效的对比观察[J].临床肝脏病杂志,2015,31(4):526-529.

[11]WAN MB,WENG XH.Several supplementary opinions to expert recommendations on interferon therapy for chronic hepatitis B[J].Chin J Infect Dis,2012,30(12):705-710.(in Chinese)万谟彬,翁心华.干扰素治疗慢性乙型肝炎专家建议的若干补充[J].中华传染病杂志,2012,30(12):705-710.

[12]FRIED MW,PIRATVISUTH T,LAU GK,et al.HBe Ag and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBe Ag-positive chronic hepatitis B[J].Hepatology,2008,47(2):428-434.

[13]LUO XD,CHEN XP,CHEN R,et al.Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBe Ag-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a[J].Chin J Hepatol,2016,24(4):241-245.(in Chinese)罗晓丹,陈小苹,陈仁,等.聚乙二醇干扰素α-2a治疗HBe Ag阳性慢性乙型肝炎24周应答不佳患者序贯替比夫定及恩替卡韦104周疗效观察[J].中华肝脏病杂志,2016,24(4):241-245.

[14]YOU J,CHEN J,YE QX,et al.Efficacy of add-on adefovir dipivoxil at week 12/24 in HBe Ag-positive chronic hepatitis B patients during PEG-IFNαtherapy[J].J Clin Hepatol,2016,32(4):687-690.(in Chinese)游佳,陈靖,叶巧霞,等.聚乙二醇干扰素α加用阿德福韦酯治疗HBe Ag阳性慢性乙型肝炎的效果观察[J].临床肝胆病杂志,2016,32(4):687-690.

[15]ZHANG Y,LYU Y,LI X,et al.Latest progress in treatment of chronic hepatitis B with tenofovir disoproxil fumarate[J].J Clin Hepatol,2015,31(4):599-602.(in Chinese)张悦,吕洋,李旭,等.替诺福韦治疗慢性乙型肝炎的最新进展[J].临床肝胆病杂志,2015,31(4):599-602.

[16]CHO HJ,KIM SS,SHIN SJ,et al.Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance[J].J Med Virol,2015,87(9):1532-1538.

[17]LEE S,PARK JY,KIM DY,et al.Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B[J].J Med Virol,2016,88(6):1027-1034.

施引文献

资源附件(0)

访问统计